Malenka Robert C. 4
4 · MapLight Therapeutics, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
MapLight Therapeutics (MPLT) Director Robert Malenka Sells Shares
What Happened
Robert C. Malenka, a director of MapLight Therapeutics, sold 12,116 shares of the company's common stock in an open-market sale on February 13, 2026. The weighted-average price reported was $18.21 per share, generating proceeds of about $220,632. The filing indicates these sales were made to cover tax obligations related to the settlement of restricted stock units (RSUs).
Key Details
- Transaction date: 2026-02-13 (reported on Form 4 filed 2026-02-18). The filing was timely (within two business days).
- Transaction type/code: Sale (S).
- Shares sold: 12,116 shares; weighted-average price: $18.21; total proceeds: $220,632.
- Price range: shares were sold in multiple transactions at prices from $18.00 to $18.59; the $18.21 is the weighted average.
- Reason noted: Sales were to cover tax withholding on RSU settlement (common practice).
- Holdings/ownership: Shares are held by the Robert C. Malenka Living Trust (Reporting Person is sole trustee with voting/dispositive power). The filing does not state the total shares owned following the sale.
- Lock-up/other restriction: The filing notes retained securities remain subject to a 180-day IPO lock-up (final prospectus dated Oct 26, 2025), through roughly April 24, 2026.
Context
Sales to cover tax withholding on RSU settlements are routine and often do not indicate a change in the insider’s view of the company. This was a disposal, not a purchase or exercise; therefore it is typically less informative about insider sentiment than buys. If you want a fuller picture, compare this sale to other recent insider transactions and the insider’s remaining holdings (not specified here).
Insider Transaction Report
- Sale
Voting Common Stock
[F1][F2]2026-02-13$18.21/sh−12,116$220,632→ 339,254 total
- 31,672(indirect: See footnote)
Voting Common Stock
[F3]
Footnotes (3)
- [F1]Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.
- [F2]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.